Updates on new therapies in development for rare liver diseases

(European Association for the Study of the Liver) Long-term data with sebelipase alfa for lysosomal acid lipase deficiency and preliminary data for investigational RNAi therapeutics for acute intermittent porphyria and alpha-1 antitrypsin deficiency add continued hope for the future management of metabolic and rare liver diseases.